ECElan A. Cohen

Elan A. Cohen

*This is an algorithmically generated author record based on publicly available information.

Elan A. Cohen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    NMDA subunit 2B-selective negative allosteric modulator satoprodil (BI 1569912) as mono- and adjunctive therapy in patients with major depressive disorder: results from two phase 2 randomized, controlled trials

    by Elan A. Cohen, Gerard Sanacora, Koichiro Watanabe, Alla Feldbarg, Rainer-Georg Goeldner, Andreas Scholz, Brittney Starling, Sigurd D. Süssmuth, J. Corey Fowler, Franco De Crescenzo

    Major depressive disorder (MDD) is a leading cause of disability worldwide, with many patients experiencing inadequate response to standard antidepressants. Dysregulation of N-methyl-D-aspartate (NMDA) receptor activity is implicated in the pathophysiology of MDD. Satoprodil (BI 1569912), an oral NMDA subunit GluN2B-selective negative allosteric modulator, was evaluated for safety and efficacy in MDD in two multicenter, randomized, placebo-controlled Phase II dose-finding trials as an adjunctive or monotherapy. In each trial, patients (18–65 years old) were randomized 2:1:1:2 to placebo or satoprodil (5 mg, 10 mg, or 20 mg) once-daily for 6 weeks, with ongoing antidepressant treatment in the adjunctive trial. Primary endpoint was change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 (both trials). Safety and tolerability were also assessed. In the adjunctive trial ( N = 243; 60.9% female), the adjusted mean (standard error [SE]) change in MADRS total score at Week 6 was: placebo, –12.0 (1.1); satoprodil 5 mg, −7.8 (1.6); satoprodil 10 mg, −11.9 (1.6) and satoprodil 20 mg, −12.3 (1.2). In the monotherapy trial ( N = 225; 54.2% female), the adjusted mean (SE) change in MADRS total score at Week 6 was: placebo, –10.3 (1.4); satoprodil 5 mg, −13.6 (2.1); satoprodil 10 mg, −10.6 (2.0) and satoprodil 20 mg, −10.0 (1.4). In patients with MDD, satoprodil (all doses) over 6-weeks was well tolerated but did not reduce depressive symptoms beyond placebo in either trial in a relevant manner. These trials provide the most comprehensive clinical evidence to date on GluN2B-selective modulation in MDD and will inform future research on glutamatergic pathways.

  • Open Access

    Safety and Efficacy of the NMDA‐2b‐Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder

    by Roger S. McIntyre, Gerard Sanacora, David P. Walling, Elan A. Cohen, Shishuka Malhotra, Holger Rosenbrock, Manuela Schmitz, Andreas Scholz, Sigurd D. Süssmuth, Franco De Crescenzo

    Selective N ‐methyl‐D‐aspartate receptor subunit 2b negative allosteric modulators (NR2B NAMs) are being explored as potential new treatment options for major depressive disorder (MDD). This Phase Ib, randomized, double‐blind, placebo‐controlled, parallel‐group trial was conducted in adults ( N = 59) with moderate‐to‐severe MDD and insufficient response to ongoing antidepressant monotherapy. Participants were randomized (1:1:1) to a novel NR2B NAM, BI 1569912 (5 mg or 20 mg tablet) or placebo. The primary safety endpoint was the number and percentage of participants with drug‐related adverse events (AEs) from the start of treatment to Day 15. Dissociation and psychedelic symptoms were assessed by the Clinician‐Administered Dissociative States Scale (CADSS) and Bowdle‐Visual Analog Scale (B‐VAS), respectively. Preliminary efficacy assessments included the maximum decrease from baseline in the Montgomery‐Åsberg Depression Rating Scale (MADRS) total score within a 7‐day interval (primary) and the change from baseline in MADRS total score at individual time points (exploratory). The proportion of participants with ≥ 1 AE was similar between BI 1569912 and placebo, with no dose‐dependent trend. There was no increase in suicidal or dissociative symptoms and no clinically relevant sign of human abuse potential. The maximum decrease from baseline in MADRS within a 7‐day interval was similar across groups; however, a single BI 1569912 20‐mg dose provided a clinically relevant 3.4‐ to 4.9‐point improvement in MADRS total score vs. placebo at Days 2, 4, and 6, meeting predefined criteria for further development. The favorable safety profile and preliminary efficacy signals support continued development of BI 1569912 for adults with MDD.